- Home
- BBBY vs LBRX Comparison
BBBY vs LBRX Comparison
Compare BBBY & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBBY | LBRX |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.5M | 602.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BBBY | LBRX |
|---|---|---|
| Price | $5.10 | $24.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 1.7M | 181.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $13.40 |
| 52 Week High | $12.65 | $25.60 |
Technical Indicators
Market Signals| Indicator | BBBY | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 54.97 |
| Support Level | $4.80 | $22.34 |
| Resistance Level | $6.72 | $24.70 |
| Average True Range (ATR) | 0.35 | 1.22 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 30.17 | 59.41 |
Price Performance
Historical ComparisonAbout BBBY Bed Bath & Beyond Inc.
Bed Bath & Beyond Inc is an ecommerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering a comprehensive array of products and services that enable its customers to enhance everyday life through quality, style, and value. The Company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites as well as a blockchain asset portfolio.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.